Qube Research & Technologies LTD Oncternal Therapeutics, Inc. Transaction History

Qube Research & Technologies LTD

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$0.29 - $0.48 $0 - $0	1 New	1 $0
Q3 2022 Nov 14, 2022	SELL	$0.83 - $17.8 $1,778 - $38,145	-2,143 Reduced 5.32%	38,151 $34,000
Q2 2022 Aug 15, 2022	BUY	$0.7 - $1.56 $28,205 - $62,858	40,294 New	40,294 $45,000
Q3 2021 Nov 12, 2021	SELL	$3.37 - $4.76 $250,232 - $353,444	-74,253 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$4.75 - $9.39 $352,701 - $697,235	74,253 New	74,253 $353,000

362K

Ticker ONCT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,517,200
Market Cap $29.4M
Description
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a smal...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.